KBY Biotech Indexv0.0.34
Search
← Pipeline|Bemaderotide

Bemaderotide

Phase 3
RVM-644
By Revolution Medicines
Source: Trial-derived·Trials: 1
Modality
Vaccine
MOA
EGFRi
Target
BCL-2
Pathway
NF-κB
ADPKDCeliacTTR Amyloidosis
Development Pipeline
Preclinical
~Jun 2019
→ ~Sep 2020
Phase 1
~Dec 2020
→ ~Mar 2022
Phase 2
~Jun 2022
→ ~Sep 2023
Phase 3
Dec 2023
→ Jun 2028
Phase 3Current
NCT03751729
1,746 pts·TTR Amyloidosis
2023-12→2028-06·Completed
1,746 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-06-152.2y awayPh3 Readout· TTR Amyloidosis
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P3
Complet…
Catalysts
Ph3 Readout
2028-06-15 · 2.2y away
TTR Amyloidosis
Completed|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT03751729Phase 3TTR AmyloidosisCompleted1746DOR
Competitors (10)
DrugCompanyPhaseTargetMOA
NiranesiranJohnson & JohnsonPhase 2KIF18AEGFRi
JNJ-5094Johnson & JohnsonPhase 2/3GIP-REGFRi
RHH-8550RocheApprovedBCL-2PRMT5i
GSK-2051GSKPhase 1PSMAEGFRi
GIL-8529Gilead SciencesPhase 1/2JAK1EGFRi
RimaglumideBiogenPhase 1/2BCL-2IL-17i
ARG-4339ArgenxPhase 2BCL-2TYK2i
GMA-729GenmabPhase 2BCL-2USP1i
HAL-996HalozymePhase 1/2BCL-2BCL-2i
207-2754Samsung BiologicsPhase 1/2KRASG12DEGFRi